C12N 2710/22034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/22034 (Use of virus or viral component as vaccine) appears on 20 US grants and 48 published applications in this corpus.
Search patents in C12N- Granted patents
- 20
- Published applications
- 48
- Assignees
- 38
- Inventors
- 86
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 3 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 4 |
| 2015 | 0 | 2 |
| 2016 | 0 | 3 |
| 2017 | 5 | 3 |
| 2018 | 2 | 4 |
| 2019 | 2 | 1 |
| 2020 | 1 | 5 |
| 2021 | 1 | 2 |
| 2022 | 2 | 3 |
| 2023 | 0 | 5 |
| 2024 | 0 | 1 |
| 2025 | 0 | 4 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Vaccine for preventing and treating Merkel cell carcinoma28 Jul 2026US 12,691,168 B2Advaccine (Suzhou) Biopharmaceuticals Co. Ltd.
- Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same13 Dec 2022US 11,524,065 B2The Wistar Institute of Anatomy and Biology
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences11 Jan 2022US 11,220,718 B2Erasmus University Medical Center Rotterdam
- Immunity inducer4 May 2021US 10,994,007 B2Saitama Medical University
- BK virus specific T cells3 Nov 2020US 10,821,134 B2Board of Regents, The University of Texas System
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Virus-specific recombinant t cell receptors and t cells comprising them20 Nov 2025US 2025/0353892 A1Bar-Ilan University
- Methods for treating cancer with activating antigen carriers23 Oct 2025US 2025/0326802 A1Stemcell Technologies Canada Inc.
- Virus-specific t cells, methods of their preparation and use thereof16 Oct 2025US 2025/0319182 A1Ministry of Health
- Fusion protein for inducing immune response and treating cancer24 Jul 2025US 2025/0235523 A1Taivital Biopharmaceutical Co. Ltd
Most cited
By later US patents
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences30US 7,449,324 B2MedImmune, LLC · 2008
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences27US 8,841,433 B2ViroNovative BV · 2014
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences22US 9,567,653 B2Erasmus University Medical Center Rotterdam · 2017
- Immortal avian cell line to grow avian and animal viruses to produce vaccines9US 5,989,805 ABoard of Trustees operating Michigan State University · 1999
- Polypeptide vaccine2US 10,258,676 B2Agency for Science, Technology and Research · 2019